Pictet & Cie (Europe) Sa Intellia Therapeutics, Inc. Transaction History

Pictet & Cie (Europe) Sa

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$53.92 - $71.7 $271,702 - $361,296	5,039 New	5,039 $282 Million
Q1 2022 May 04, 2022	SELL	$58.27 - $118.99 $134,487 - $274,628	-2,308 Closed	0 $0
Q4 2021 Feb 02, 2022	BUY	$100.76 - $138.36 $232,554 - $319,334	2,308 New	2,308 $273,000

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $775M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Pictet & Cie (Europe) Sa, based on Form 13F filings with the SEC.

Stay updated on Pictet & Cie (Europe) Sa with notifications on news.